睿知中国疾病研究地图
候选清单0

正在招募多发性骨髓瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 12 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 12

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  2. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  3. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  4. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  5. 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
  6. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
  7. 研究中心南方医科大学南方医院Nanfang Hospital广州医院页面
  8. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  9. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  10. 研究中心同济大学附属上海市第四人民医院Shanghai Fourth People's Hospital上海医院页面
  11. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  12. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05623020,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Part 1: Participants with relapsed/refractory multiple myeloma (RRMM) who have received 1-2 prior lines of therapy including at least one immunomodulatory drug and one proteasome inhibitor: or participants with newly-diagnosed multiple myeloma (NDMM) that are transplant-ineligible as defined by age ≥65 years or transplant-ineligible as defined by age <65 years with comorbidities impacting the possibility of transplant.

    入选标准第 6 条

    For participants with RRMM: Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

    入选标准第 12 条

    For participants with RRMM: Previous treatment with a BCMA-directed therapy or anti-CD38-directed therapy within 6 months preceding the first dose of study intervention in this study. Stem cell transplant ≤3 months prior to first dose of study intervention or active GVHD.

    排除标准第 7 条

    For participants with NDMM: Previous systemic treatment for MM except for a short course of corticosteroids (ie, total of 160 mg dexamethasone or equivalent before the first dose of study intervention). A cumulative dose of systemic corticosteroids equivalent to ≥20 mg of dexamethasone during screening.

    排除标准第 8 条

  3. ECOG performance status ≤2.

    入选标准第 10 条

  4. Measurable disease based on IMWG criteria as defined by at least 1 of the following:

    入选标准第 2 条

  5. Not pregnant and willing to use contraception

    入选标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05623020,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Diagnosis of multiple myeloma (MM) as defined by IMWG criteria (Rajkumar et al., 2014)
  2. Measurable disease based on IMWG criteria as defined by at least 1 of the following:
  3. Serum M-protein ≥0.5 g/dL (Part 1) and ≥1 g/dL (Part 2);
  4. Urinary M-protein excretion ≥200 mg/24 hours;
  5. Involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
  6. Part 1: Participants with relapsed/refractory multiple myeloma (RRMM) who have received 1-2 prior lines of therapy including at least one immunomodulatory drug and one proteasome inhibitor: or participants with newly-diagnosed multiple myeloma (NDMM) that are transplant-ineligible as defined by age ≥65 years or transplant-ineligible as defined by age <65 years with comorbidities impacting the possibility of transplant.
  7. Part 2: participants with newly-diagnosed multiple myeloma that are transplant-ineligible defined as:
  8. Participants not considered candidates for high-dose chemotherapy and ASCT due to age or
  9. Participants with important comorbidities likely to have a negative impact on tolerability of high dose chemotherapy and ASCT.
  10. ECOG performance status ≤2.
  11. Not pregnant and willing to use contraception
  12. For participants with RRMM: Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

排除标准:Exclusion Criteria:

  1. Smoldering Multiple Myeloma.
  2. Monoclonal gammopathy of undetermined significance.
  3. Waldenströms Macroglobulinemia
  4. Plasma cell leukemia.
  5. Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19/SARS-CoV-2, HBV, HCV, and known HIV or AIDS-related illness.
  6. Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or Stage 0/1 with minimal risk of recurrence per investigator.
  7. For participants with RRMM: Previous treatment with a BCMA-directed therapy or anti-CD38-directed therapy within 6 months preceding the first dose of study intervention in this study. Stem cell transplant ≤3 months prior to first dose of study intervention or active GVHD.
  8. For participants with NDMM: Previous systemic treatment for MM except for a short course of corticosteroids (ie, total of 160 mg dexamethasone or equivalent before the first dose of study intervention). A cumulative dose of systemic corticosteroids equivalent to ≥20 mg of dexamethasone during screening.
  9. Live attenuated vaccine administered within 4 weeks of the first dose of study intervention.
  10. Administration of investigational product (eg, drug or vaccine) concurrent with study intervention or within 30 days (or as determined by the local requirement) preceding the first dose of study intervention used in this study.

引自 ClinicalTrials.gov, NCT05623020, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05623020,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05623020